Affordable Access

Publisher Website

Outcomes of treatment with sirolimus for non-infectious uveitis: a meta-analysis and systematic review.

  • Cabahug, Vicente Lorenzo O1
  • Uy, Harvey S1, 2
  • Yu-Keh, Ellen1
  • Sapno, Kristine Joy D3
  • 1 St Luke's Medical Center, Quezon City, Philippines, [email protected] , (Philippines)
  • 2 University of the Philippines, Manila, Philippines. , (Philippines)
  • 3 University of Santo Tomas Hospital, Manila, Philippines. , (Philippines)
Published Article
Clinical ophthalmology (Auckland, N.Z.)
Publication Date
Jan 01, 2019
DOI: 10.2147/OPTH.S198401
PMID: 31114144


Uveitis is a group of intraocular inflammatory diseases whose primary treatment involves immunosuppression. Although corticosteroids (CSs) remain the mainstay therapy, sirolimus is among the recently studied immunomodulatory drugs for treating noninfectious uveitis (NIU). The aim of this review was to assess and summarize the updated evidence on the outcomes of treatment with sirolimus for NIU. Two reviewers conducted a systematic search on November 5, 2018, of electronic databases (EMBASE, MEDLINE, and The Cochrane Library) and clinical trial registers having no restrictions on language or publication date. The primary outcome was uveitis activity as measured by vitreous haze (VH), while the secondary outcomes included central macular thickness (CMT), best-corrected visual acuity (BCVA), CS-sparing effect, IOP elevation, and other adverse events. A meta-analysis was conducted on selected studies with appropriate clinical and methodological homogeneity. Seven studies were included and reviewed. Four randomized clinical trials were eligible for meta-analysis: SAVE 2013, One-year outcomes of the SAVE study, SAVE 2 2016, SAKURA 2016. The pooled proportions of inflammation control (VH improvement) were 38% (95% CI 16.19%-62.66%) during a 6-month follow-up and 49.97% (95% CI 16.19%-83.03%) during a 6- to 12-month follow-up with the latter showing a significantly higher response rate (p=0.0472). BCVA improvement was 62.2% (95% CI 33.17%-87.11%) during a 6-month follow-up and 56.86% (95% CI 20.91%-89.05%) during a 6- to 12-month follow-up with no significant difference between the two (p=0.3705). Increased IOP remained at 7.11% (95% CI 3.46%-12.68%) for both a 6-month follow-up and up to a 12-month follow-up duration. The CS-sparing effect of sirolimus was also well demonstrated. A reduction in CMT was observed, and only minor drug-related adverse events were reported in all the studies reviewed. This review provided evidence that sirolimus is a promising treatment option for controlling inflammatory activity, improving visual acuity, and sparing CS use with minor adverse events for NIU.

Report this publication


Seen <100 times